ReviewiScience2022
The role of
Review in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 84 citations in OpenAlex.
- Repurposing of Clomiphene Citrate and Its Antileishmanial and Antifungal Activities:Biomolecules · 2026Article
- Ligand-mediated conformation diversity of Hsp90 revealed by GaMD simulations and Markov model.Molecular diversity · 2026Article
- Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin inJAC-antimicrobial resistance · 2026Article
- Uncovering actionable trade-offs of antifungal resistance in a yeast pathogen.Molecular systems biology · 2026Article
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Cell Wall Proteome ofPathogens (Basel, Switzerland) · 2026Article
- Comprehensive Insights into Sugar Transporters ofJournal of fungi (Basel, Switzerland) · 2026Article
- OvercomingFrontiers in antibiotics · 2026Review
- Article
- Antifungal Efficacy of Plasma-Activated Liquids againstACS omega · 2025Article
- Proteomic Analysis Revealed that DVL, a Lectin Purified fromACS omega · 2025Article
- Antifungal persistence: Clinical relevance and mechanisms.PLoS pathogens · 2025Review
- Host-specific adaptation inmBio · 2025Article
- In vitro and in vivo antifungal activity of Minocycline albumin nanoparticles in combination with fluconazole against azole-resistant Candida spp.BMC microbiology · 2025Article
- Structure-activity Relationship for Diarylpyrazoles as Inhibitors of the Fungal Kinase Yck2.bioRxiv : the preprint server for biology · 2025Article
- Adaptive morphological changes link to poor clinical outcomes by conferring echinocandin tolerance in Candida tropicalis.PLoS pathogens · 2025Article
- Virulence ofbioRxiv : the preprint server for biology · 2025Article
- Signaling Pathways Regulating Dimorphism in Medically Relevant Fungal Species.Pathogens (Basel, Switzerland) · 2025Review
- Induction of Antifungal Tolerance Reveals Genetic and Phenotypic Changes inJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human fungal pathogens are the causative agents of devastating diseases across the globe, and the increasing prevalence of drug resistance threatens to undermine the already limited treatment options. One prominent pathogen is the opportunistic fungus
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.